These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14533836)

  • 1. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL; Norwood C; Stashower ME
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal melanonychia induced by capecitabine.
    Paravar T; Hymes SR
    Dermatol Online J; 2009 Oct; 15(10):11. PubMed ID: 19951629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 6. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
    Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
    Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
    [No Abstract]   [Full Text] [Related]  

  • 7. Onycholysis associated with capecitabine in patients with breast cancer.
    Hogeling M; Howard J; Kanigsberg N; Finkelstein H
    J Cutan Med Surg; 2008; 12(2):93-5. PubMed ID: 18346407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine induced cutaneous hyperpigmentation: report of a case.
    Pui JC; Meehan S; Moskovits T
    J Drugs Dermatol; 2002 Sep; 1(2):202-5. PubMed ID: 12847748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
    Tejera A; Bosch RJ; López N; Herrera E
    Actas Dermosifiliogr; 2006 Oct; 97(8):536-8. PubMed ID: 17067535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Tavares-Bello R
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
    [No Abstract]   [Full Text] [Related]  

  • 11. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and PPE syndrome: a case report.
    LoRusso PM
    Breast J; 2003; 9(1):64-5. PubMed ID: 12558679
    [No Abstract]   [Full Text] [Related]  

  • 13. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
    Sauter C; Saborowski A; Ockenfels HM
    Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hand and foot syndrome secondary to capecitabine.
    Lal HS
    Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine induced inflammation of actinic keratoses.
    Krathen M; Treat J; James WD
    Dermatol Online J; 2007 Oct; 13(4):13. PubMed ID: 18319010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nail and periungual toxicity following capecitabine therapy.
    Vaccaro M; Barbuzza O; Guarneri F; Guarneri B
    Br J Clin Pharmacol; 2008 Aug; 66(2):325-6. PubMed ID: 18384441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.